Executive Summary
Dr. Deepak Behera is a nuclear medicine physician and pharmaceutical executive with more than 25 years spanning radiopharmaceuticals, molecular imaging, clinical development, medical affairs, and translational research. From building PET imaging probes and translating preclinical programs into early-phase clinical trials at Stanford, to leading medical affairs for clinical-stage biotechs, he pairs deep bench-to-bedside science with hands-on executive operating experience.
As a Senior Partner at The Bracken Group, Deepak advises biotech, pharma, radiopharmaceutical, diagnostic, and device clients on clinical development strategy, FDA interactions, medical affairs build-out, imaging and dosimetry endpoints, pharmacovigilance, and M&A and licensing due diligence. His therapeutic reach spans oncology, immuno-oncology, neurology, and pain, with particular depth in theranostics and PET imaging. He has served as a fractional Chief Medical Officer and strategic medical director, helped turn around stalled trials, supported FDA alignment on Phase 3 designs, and built medical affairs teams and launch strategies from the ground up.
Clients engage Deepak when a radiopharmaceutical or imaging-driven program needs a physician-executive who can connect first-in-human science to registrational strategy — and translate complex clinical data for boards, investors, regulators, and key opinion leaders alike.
Areas of Expertise
Radiopharmaceuticals & Theranostics
Clinical development and medical strategy for radioconjugates, theranostic agents, and radiotherapeutics — from first-in-human studies through registrational trials.
Nuclear Medicine & Molecular Imaging
PET/SPECT imaging, tracer development, dosimetry, imaging biomarkers, and reader training across oncology and neurology programs.
Clinical Development Strategy
Phase 1–3 and registrational trial design, endpoint and target product profile logic, clinical/regulatory roadmaps, and evidence-generation planning.
FDA & Regulatory Interactions
Pre-IND/IND, Type C/D, end-of-Phase 2, and NDA/505(b)(2)-adjacent strategy, including agency-facing clinical, safety, and regulatory-response materials.
Medical Affairs & Launch Strategy
Building medical affairs teams, MSL and KOL programs, advisory boards, publication strategy, and pre- and post-launch evidence generation.
Medical Monitoring & Pharmacovigilance
Safety surveillance planning, medical monitoring, vendor selection, and pharmacovigilance oversight across early- and late-phase clinical trials.
M&A & Licensing Due Diligence
Clinical, scientific, and commercial diligence for licensing, acquisition, and investment decisions, with product-market fit and path-to-approval assessment.
CRO / Site / Vendor Oversight
Protocol and study-document drafting, site and investigator selection, imaging charters and manuals, and clinical operations oversight.